Crm1 knockdown by specific small interfering RNA reduces cell proliferation and induces apoptosis in head and neck cancer cell lines
Head and neck squamous cell carcinoma (HNSCC) is the most common and most aggressive type of head and neck cancer.
Current approaches for the treatment of HNSCC are not sufficient to increase the patient survival or to reduce the high recurrence
rate. Consequently, there is a need to explore the molecular characteristics of this cancer in order to discover potential therapeutic
target molecules. The overexpression of chromosome region maintenance 1 (Crm1), responsible for the transport of different classes of
macromolecules from the nuclear membrane to the cytoplasm, in various cancer cells has made it an attractive target molecule in cancer
research. It has been reported that transcription factors, which are the target cargo proteins of Crm1, have critical roles in regulating
intracellular processes via their expression levels and functions, which in turn are regulated by the cell cycle and signaling proteins.
Previous findings show that head and neck cancer cells overexpress Crm1 and that these cells become highly dependent on Crm1
function. The results of this study show that after decreasing Crm1 expression levels in HNSCC cells through either treatment with
specific Crm1 RNA interference (siRNA) or the selective Crm1 inhibitor leptomycin B (LMB), cell viability, proliferation, migration,
and wound-healing abilities decreased, suppressing tumorigenic properties through the induction of apoptosis. Crm1 is a powerful
diagnostic biomarker because of its central role in cancerogenesis, and it has a high potential for the development of targeted Crm1
molecules or synthetic agents, such as LMB, as well as for the improvement of the clinical features in head and neck cancer.
___
- Bender O, Gunduz M, Cigdem S, Hatipoglu OF, Acar M, Kaya M,
Grenman R, Gunduz E, Ugur KS (2018). Functional analysis
of ESM1 by siRNA knockdown in primary and metastatic head
and neck cancer cells. J Oral Pathol Med 47: 40-47.
- Brodie KM, Henderson BR (2012). Characterization of BRCA1
protein targeting, dynamics, and function at the centrosome. A
role for the nuclear export signal, CRM1, and Aurora A kinase.
J Biol Chem 287: 7701-7716.
- Chan CY, Lien CH, Lee MF, Huang CY (2016). Quercetin suppresses
cellular migration and invasion in human head and neck
squamous cell carcinoma (HNSCC). Biomedicine (Taipei) 6:
15.
- Chan KS, Wong CH, Huang YF, Li HY (2010). Survivin withdrawal
by nuclear export failure as a physiological switch to commit
cells to apoptosis. Cell Death Dis 1: e57.
- Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E,
Pavlakis GN, Vandamme AM (2002). A synthetic HIV-1 Rev
inhibitor interfering with the CRM1-mediated nuclear export.
P Natl Acad Sci USA 99: 14440-14445.
- Easty D, Easty G, Carter R, Monaghan P, Butler L (1981). Ten human
carcinoma cell lines derived from squamous carcinomas of the
head and neck. Br J Cancer 43: 772-785.
- Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida
M, Nishida E (1997). CRM1 is responsible for intracellular
transport mediated by the nuclear export signal. Nature 390:
308-311.
- Fung HY, Chook YM (2014). Atomic basis of CRM1-cargo
recognition, release and inhibition. Semin Cancer Biol 27: 52-
61.
- Henderson BR (2000). Nuclear cytoplasmic shuttling of APC
regulates beta catenin subcellular localization and turnover.
Nat Cell Biol 2: 653-660.
- Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M (2015). Expression,
function, and targeting of the nuclear exporter chromosome
region maintenance 1 (CRM1) protein. Pharmacol Ther 153:
25-35.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer
statistics. CA Cancer J Clin 59: 225-249.
- Kaomongkolgit R (2013). Alpha-mangostin suppresses MMP-2 and
MMP-9 expression in head and neck squamous carcinoma
cells. Odontology 101: 227-232.
- Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ,
Roberts TM, Clardy J, Sellers WR, Silver PA (2003). A chemical
genetic screen identifies inhibitors of regulated nuclear export
of a Forkhead transcription factor in PTEN-deficient tumor
cells. Cancer Cell 4: 463-476.
- Kau TR, Way JC, Silver PA (2004). Nuclear transport and cancer:
from mechanism to intervention. Nat Rev Cancer 4: 106-117.
- Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida
M, Horinouchi S (1997). Molecular cloning and cell cycle
dependent expression of mammalian CRM1, a protein involved
in nuclear export of proteins. J Biol Chem 272: 29742-29751.
- Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner, EP, Wolff
B, Yoshida M, Horinouchi S (1999). Leptomycin B inactivates
CRM1/exportin 1 by covalent modification at a cysteine
residue in the central conserved region. P Natl Acad Sci USA
96: 9112-9117.
- Kuusisto HV, Wagstaff KM, Alvisi G, Roth DM, Jans DA (2011).
Global enhancement of nuclear localization-dependent
nuclear transport in transformed cells. FASEB J 26: 1181-1193.
- Lange MJ, Lasiter JC, Misfeldt ML (2009). Toll-like receptors in
tonsillar epithelial cells. Int J Pediatr Otorhinolaryngol 73:
613-621.
- Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch
WM, Ferris RL, Lai SY (2007). Head and neck squamous cell
carcinoma cell lines: established models and rationale for
selection. Head Neck 29: 163-188.
- Liu X, Chong Y, Liu H, Han Y, Niu M (2016). CRM1 inhibitor S109
suppresses cell proliferation and induces cell cycle arrest in
renal cancer cells. Korean J Physiol Pharmacol 20: 161-168.
- Mao L, Hong WK, Papadimitrakopoulou VA (2004). Focus on head
and neck cancer. Cancer Cell 5: 311-316.
- Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard
L, Meani N, Bergomas R, Alcalay M, Pelicci PG (2006).
Cytoplasmic localization of NPM in myeloid leukemias is
dictated by gain of function mutations that create a functional
nuclear export signal. Oncogene 25: 4376-4380.
- Maushagen R, Reers S, Pfannerstill AC, Hahlbrock A, Stauber R,
Rahmanzadeh R, Rades D, Pries R, Wollenberg B (2016).
Effects of paclitaxel on permanent head and neck squamous
cell carcinoma cell lines and identification of anti-apoptotic
caspase 9b. J Cancer Res Clin Oncol 142: 1261-1271.
- Newlands ES, Rustin GJ, Brampton MH (1996). Phase I trial of
elactocin. Br J Cancer 74: 648-649.
- Nguyen KT, Holloway MP, Altura RA (2012). The XPO1 nuclear
export protein in normal development and disease. Int J
Biochem Mol Biol 3: 137-151.
- Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch
I, Sehouli J, Dietel M, Denkert C (2008). Expression of the
nuclear export protein chromosomal region maintenance/
exportin 1/Xpo1 is a prognostic factor in human ovarian
cancer. Cancer 112: 1733-1743.
- Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM,
Kufe DW, Vonhoff DD, Iwami T, Kawabe T (2011). CBS9106 is
a novel reversible oral CRM1 inhibitor with CRM1 degrading
activity. Blood 118: 3922-3931.
- Santiago A, Li D, Zhao LY, Godsey A, Liao D (2013). p53
SUMOylation promotes its nuclear export by facilitating its
release from the nuclear export receptor CRM1. Mol Biol Cell
24: 2739-2752.
- Saussez S, Decaestecker C, Mahillon V, Cludts S, Capouillez A,
Chevalier D, Vet HK, André S, Toubeau G, Leroy X et al.
(2008). Galectin-3 upregulation during tumor progression in
head and neck cancer. Laryngoscope 118: 1583-1590.
- Shao WY, Yang YL, Yan H, Huang Q, Liu KJ, Zhang S (2017).
Phenethyl isothiocyanate suppresses the metastasis of ovarian
cancer associated with the inhibition of CRM1-mediated
nuclear export and mTOR-STAT3 pathway. Cancer Biol Ther
18: 26-35.
- Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B,
Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N
et al. (2008). Expression and mutation analysis of epidermal
growth factor receptor in head and neck squamous cell
carcinoma. Cancer Sci 99: 1589-1594.
- Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C (2009). Expression of
CRM1 in human gliomas and its significance in p27 expression
and clinical prognosis. Neurosurgery 65: 153-159.
- Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA
Cancer J Clin 64: 9-29.
- Stell PM (1989). Survival times in end-stage head and neck cancer.
Eur J Surg Oncol 15: 407-410.
- Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M,
Tannenbaum D, Cagnetta A, Reagan M, Munshi AA et al.
(2014). CRM1 inhibition induces tumor cell cytotoxicity and
impairs osteoclastogenesis in multiple myeloma: molecular
mechanisms and therapeutic implications. Leukemia 28: 155-
165.
- Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR,
Bresalier RS, Raz A (2004). Nuclear export of phosphorylated
galectin-3 regulates its antiapoptotic activity in response to
chemotherapeutic drugs. Mol Cell Biol 24: 4395-4406.
- Tamura S, Shiomi A, Kaneko M, Ye Y, Yoshida M, Yoshikawa M,
Kimura T, Kobayashi M, Murakami N (2009). New Rev-
export inhibitor from
Alpinia galanga
and structure-activity
relationship. Bioorg Med Chem Lett 19: 2555-2557.
- Turner JG, Dawson J, Sullivan DM (2011). CRM1-mediated nuclear
export of proteins and drug resistance in cancer. Curr Med
Chem 15: 2648-2655.
- Turner JG, Dawson J, Sullivan DM (2012). Nuclear export of proteins
and drug resistance in cancer. Biochem Pharmacol 83: 1021-
1032.
- van der Watt PJ, Leaner VD (2011). The nuclear exporter, Crm1, is
regulated by NFY and Sp1 in cancer cells and repressed by p53
in response to DNA damage. Biochim Biophys Acta 1809: 316-
326.
- van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L,
Govender D, Birrer MJ, Leaner VD (2009). The Karyopherin
proteins, Crm1 and Karyopherin β1, are overexpressed in
cervical cancer and are critical for cancer cell survival and
proliferation. Int J Cancer 124: 1829-1840.
- van der Watt PJ, Zemanay W, Govender D, Hendricks DT, Parker
MI, Leaner VD (2014). Elevated expression of the nuclear
export protein, Crm1 (exportin 1), associates with human
oesophageal squamous cell carcinoma. Oncol Rep 32: 730-738.
- Wilken B, Veena MS, Wang MB, Srivatsan ES (2011). Curcumin: A
review of anti-cancer properties and therapeutic activity in
head and neck squamous cell carcinoma. Mol Cancer 10: 12.
- Wolff B, Sanglier JJ, Wang Y (1997). Leptomycin B is an inhibitor of
nuclear export: inhibition of nucleo-cytoplasmic translocation
of the human immunodeficiency virus type 1 (HIV-1) Rev
protein and Rev-dependent mRNA. Chem Biol 4: 139-147.
- Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X, Chen X, Zhang J,
Li M (2014). Involvement of chromosome region maintenance
1 (CRM1) in the formation and progression of esophageal
squamous cell carcinoma. Med Oncol 31: 155.
- Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN,
Zheng SE (2009). The expression of CRM1 is associated with
prognosis in human osteosarcoma. Oncol Rep 21: 229-235.
- Yashiroda Y, Yoshida M (2003). Nucleo-cytoplasmic transport of
proteins as a target for therapeutic drugs. Curr Med Chem 10:
741-748.
- Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A (2002).
Galectin-3 phosphorylation is required for its anti-apoptotic
function and cell cycle arrest. J Biol Chem 277: 6852-6857.
- Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S, Lv J, Yue L (2013). CRM1
is a novel independent prognostic factor for the poor prognosis
of gastric carcinomas. Med Oncol 30: 726.